Research Article

Minimal clinically important change on the unified Parkinson's disease rating scale

  1. Anette Schrag MD, PhD1,*,
  2. Cristina Sampaio MD, PhD2,
  3. Nicholas Counsell BSc3,
  4. Werner Poewe MD4

Article first published online: 3 MAY 2006

DOI: 10.1002/mds.20914

Issue

Movement Disorders

Movement Disorders

Volume 21, Issue 8, pages 1200–1207, August 2006

Additional Information

How to Cite

Schrag, A., Sampaio, C., Counsell, N. and Poewe, W. (2006), Minimal clinically important change on the unified Parkinson's disease rating scale. Mov. Disord., 21: 1200–1207. doi: 10.1002/mds.20914

Author Information

  1. 1

    Royal Free and University College Medical School, University College London, London, United Kingdom

  2. 2

    Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal

  3. 3

    GlaxoSmithKline, Harlow, United Kingdom

  4. 4

    Department of Neurology, University Clinic, Innsbruck, Austria

*Royal Free and University College Medical School, University College London, London NW3 2PF, United Kingdom

Publication History

  1. Issue published online: 22 AUG 2006
  2. Article first published online: 3 MAY 2006
  3. Manuscript Accepted: 6 JAN 2006
  4. Manuscript Revised: 28 DEC 2005
  5. Manuscript Received: 14 AUG 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (76K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paula Lauhoff, Niamh Murphy, Colin Doherty, N. Frances Horgan, A controlled clinical trial investigating the effects of cycle ergometry training on exercise tolerance, balance and quality of life in patients with Parkinson’s disease, Disability and Rehabilitation, 2013, 35, 5, 382

    CrossRef

  2. 2
    Camille P. Vaughan, Jorge L. Juncos, Lynn Marie Trotti, Theodore M. Johnson, Donald L. Bliwise, Nocturia and overnight polysomnography in Parkinson disease, Neurourology and Urodynamics, 2013, 32, 4
    Direct Link:
  3. 3
    Samuel D. Kim, Natalie E. Allen, Colleen G. Canning, Victor S. C. Fung, Postural Instability in Patients with Parkinson’s Disease, CNS Drugs, 2013, 27, 2, 97

    CrossRef

  4. 4
    A. H. V. Schapira, P. Barone, R. A. Hauser, Y. Mizuno, O. Rascol, M. Busse, C. Debieuvre, M. Fraessdorf, W. Poewe, Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease, European Journal of Neurology, 2013, 20, 1
    Direct Link:
  5. 5
    Anthony E. Lang, Eldad Melamed, Werner Poewe, Olivier Rascol, Trial designs used to study neuroprotective therapy in Parkinson's disease, Movement Disorders, 2013, 28, 1
    Direct Link:
  6. 6
    Martin Wolz, Christine Schleiffer, Lisa Klingelhöfer, Christine Schneider, Florian Proft, Uta Schwanebeck, Heinz Reichmann, Peter Riederer, Alexander Storch, Comparison of chocolate to cacao-free white chocolate in Parkinson’s disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial, Journal of Neurology, 2012, 259, 11, 2447

    CrossRef

  7. 7
    Thuy C. Vu, John G. Nutt, Nicholas H. G. Holford, Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease, British Journal of Clinical Pharmacology, 2012, 74, 2
    Direct Link:
  8. 8
    Dag Nyholm, Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety, Parkinsonism & Related Disorders, 2012, 18, 8, 916

    CrossRef

  9. 9
    Carlos Ayán, José Cancela, Feasibility of 2 Different Water-Based Exercise Training Programs in Patients With Parkinson's Disease: A Pilot Study, Archives of Physical Medicine and Rehabilitation, 2012, 93, 10, 1709

    CrossRef

  10. 10
    Wolfgang H. Jost, Michael Friede, Jörg Schnitker, Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease, Basal Ganglia, 2012, 2, 4, S17

    CrossRef

  11. 11
    Miguel Coelho, Joaquim J. Ferreira, Late-stage Parkinson disease, Nature Reviews Neurology, 2012,

    CrossRef

  12. 12
    Claire Hinnell, Catherine S. Hurt, Sabine Landau, Richard G. Brown, Michael Samuel, Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?, Movement Disorders, 2012, 27, 2
    Direct Link:
  13. 13
    Ruiping Xia, Zhi-Hong Mao, Progression of motor symptoms in Parkinson’s disease, Neuroscience Bulletin, 2012, 28, 1, 39

    CrossRef

  14. 14
    Fabian J. David, Miriam R. Rafferty, Julie A. Robichaud, Janey Prodoehl, Wendy M. Kohrt, David E. Vaillancourt, Daniel M. Corcos, Progressive Resistance Exercise and Parkinson's Disease: A Review of Potential Mechanisms, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  15. 15
    Robert D. Altman, Anthony E. Lang, Ronald B. Postuma, Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study, Movement Disorders, 2011, 26, 13
    Direct Link:
  16. 16
    Matthias Löhle, Heinz Reichmann, Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease, BMC Neurology, 2011, 11, 1, 112

    CrossRef

  17. 17
    Robert A. Hauser, Peggy Auinger, Determination of minimal clinically important change in early and advanced Parkinson's disease, Movement Disorders, 2011, 26, 5
    Direct Link:
  18. 18
    Dee E. Silver, Philip O. Buck, Determining the Efficacy of Rasagiline in Reducing Bradykinesia Among Parkinson's Disease Patients: A Review, International Journal of Neuroscience, 2011, 121, 9, 485

    CrossRef

  19. 19
    Claire Henchcliffe, W. Lawrence Severt, Disease Modification in Parkinsonʼs Disease, Drugs & Aging, 2011, 28, 8, 605

    CrossRef

  20. 20
    I. Reuter, S. Mehnert, P. Leone, M. Kaps, M. Oechsner, M. Engelhardt, Effects of a Flexibility and Relaxation Programme, Walking, and Nordic Walking on Parkinson's Disease, Journal of Aging Research, 2011, 2011, 1

    CrossRef

  21. 21
    Ho-Won Lee, Jihye Choi, Kyoungho Suk, Increases of pentraxin 3 plasma levels in patients with Parkinson's disease, Movement Disorders, 2011, 26, 13
    Direct Link:
  22. 22
    Anne N. Nisenzon, Michael E. Robinson, Dawn Bowers, Evangelia Banou, Irene Malaty, Michael S. Okun, Measurement of patient-centered outcomes in Parkinson’s disease: What do patients really want from their treatment?, Parkinsonism & Related Disorders, 2011, 17, 2, 89

    CrossRef

  23. 23
    Yvette M. Bordelon, Ron D. Hays, Stefanie D. Vassar, Natalie Diaz, Jeff Bronstein, Barbara G. Vickrey, Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  24. 24
    C. Warren Olanow, Kathryn B. Wunderle, Karl Kieburtz, Milestones in movement disorders clinical trials: Advances and landmark studies, Movement Disorders, 2011, 26, 6
    Direct Link:
  25. 25
    Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley, Richard Gray, Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?, Movement Disorders, 2011, 26, 7
    Direct Link:
  26. 26
    Kamal Shemisa, Chris J. Hass, Kelly D. Foote, Michael S. Okun, Samuel S. Wu, Charles E. Jacobson, Yunfeng Dai, Genko Oyama, Hubert H. Fernandez, Unilateral deep brain stimulation surgery in Parkinson’s disease improves ipsilateral symptoms regardless of laterality, Parkinsonism & Related Disorders, 2011, 17, 10, 745

    CrossRef

  27. 27
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  28. 28
    Georg Ebersbach, Almut Ebersbach, Daniela Edler, Olaf Kaufhold, Matthias Kusch, Andreas Kupsch, Jörg Wissel, Comparing exercise in Parkinson's disease—the Berlin BIG Study, Movement Disorders, 2010, 25, 12
    Direct Link:
  29. 29
    Adrian Williams, Steven Gill, Thelekat Varma, Crispin Jenkinson, Niall Quinn, Rosalind Mitchell, Richard Scott, Natalie Ives, Caroline Rick, Jane Daniels, Smitaa Patel, Keith Wheatley, Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial, The Lancet Neurology, 2010, 9, 6, 581

    CrossRef

  30. 30
    DAN HURLEY, Does Statistical Significance Translate Into Clinical Efficacy?, Neurology Today, 2010, 10, 6, 4

    CrossRef

  31. 31
    Olivier Rascol, Paolo Barone, Robert A. Hauser, Yoshikuni Mizuno, Werner Poewe, Anthony H.V. Schapira, Laurence Salin, Mandy Sohr, Catherine Debieuvre, Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease, Movement Disorders, 2010, 25, 14
    Direct Link:
  32. 32
    Kenneth A. Follett, Frances M. Weaver, Matthew Stern, Kwan Hur, Crystal L. Harris, Ping Luo, William J. Marks, Johannes Rothlind, Oren Sagher, Claudia Moy, Rajesh Pahwa, Kim Burchiel, Penelope Hogarth, Eugene C. Lai, John E. Duda, Kathryn Holloway, Ali Samii, Stacy Horn, Jeff M. Bronstein, Gatana Stoner, Philip A. Starr, Richard Simpson, Gordon Baltuch, Antonio De Salles, Grant D. Huang, Domenic J. Reda, Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease, New England Journal of Medicine, 2010, 362, 22, 2077

    CrossRef

  33. 33
    Angelo Antonini, Paolo Barone, Roberto Ceravolo, Giovanni Fabbrini, Michele Tinazzi, Giovanni Abbruzzese, Role of Pramipexole in the Management of Parkinsonʼs Disease, CNS Drugs, 2010, 24, 10, 829

    CrossRef

  34. 34
    Werner Poewe, Clinical measures of progression in Parkinson's disease, Movement Disorders, 2009, 24, S2
    Direct Link:
  35. 35
    Robert A. Hauser, Michel Panisset, Giovanni Abbruzzese, Linda Mancione, Nalina Dronamraju, Algirdas Kakarieka, Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease, Movement Disorders, 2009, 24, 4
    Direct Link:
  36. 36
    Ripple Talati, Kurt Reinhart, William Baker, C. Michael White, Craig I. Coleman, Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors, Parkinsonism & Related Disorders, 2009, 15, 7, 500

    CrossRef

  37. 37
    Werner Poewe, Philipp Mahlknecht, The clinical progression of Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S28

    CrossRef

  38. 38
    Vladimir S. Kostić, Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists, Parkinsonism & Related Disorders, 2009, 15, S71

    CrossRef

  39. 39
    Han-Joon Kim, Sun Ha Paek, Ji-Young Kim, Jee-Young Lee, Yong Hoon Lim, Dong Gyu Kim, Beom S. Jeon, Two-year follow-up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease, Movement Disorders, 2009, 24, 3
    Direct Link:
  40. 40
    Joseph Jankovic, Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?, Annals of Neurology, 2008, 63, 3
    Direct Link:
  41. 41
    Carl E. Clarke, Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?, Movement Disorders, 2008, 23, 6
    Direct Link:
  42. 42
    M.H. Nilsson, G.-B. Jarnlo, S. Rehncrona, Functional balance performance in patients with Parkinson's disease after long-term treatment with subthalamic nucleus high-frequency stimulation, Parkinsonism & Related Disorders, 2008, 14, 4, 291

    CrossRef

  43. 43
    Jordi Clarimón, Javier Pagonabarraga, Coro Paisán-Ruíz, Antonia Campolongo, Berta Pascual-Sedano, José-Félix Martí-Massó, Andrew B. Singleton, Jaime Kulisevsky, Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening, Movement Disorders, 2008, 23, 4
    Direct Link:
  44. 44
    N.J. Diederich, L. Verhagen Metman, R.A. Bakay, F. Alesch, Ventral Intermediate Thalamic Stimulation in Complex Tremor Syndromes, Stereotactic and Functional Neurosurgery, 2008, 86, 3, 167

    CrossRef

  45. 45
    Pablo Martinez-Martin, Günther Deuschl, Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Movement Disorders, 2007, 22, 6
    Direct Link:
  46. 46
    Susanne May, Sid Gilman, B. Brooke Sowell, Ronald G. Thomas, Matthew B. Stern, Amy Colcher, Caroline M. Tanner, Neng Huang, Peter Novak, Stephen G. Reich, Joseph Jankovic, William G. Ondo, Phillip A. Low, Paola Sandroni, Axel Lipp, Frederick J. Marshall, Frederick Wooten, Clifford W. Shults, Potential outcome measures and trial design issues for multiple system atrophy, Movement Disorders, 2007, 22, 16
    Direct Link:
  47. 47
    Christopher G. Goetz, Philippe Damier, Christine Hicking, Eugene Laska, Thomas Müller, C. Warren Olanow, Olivier Rascol, Hermann Russ, Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial, Movement Disorders, 2007, 22, 2
    Direct Link:
  48. 48
    Ali Samii, Valerie E. Kelly, Jefferson C. Slimp, Anne Shumway-Cook, Robert Goodkin, Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson disease, Movement Disorders, 2007, 22, 10
    Direct Link:
  49. 49
    Claire L Tomlinson, Smitaa Patel, Charmaine Meek, Carl E Clarke, Rebecca Stowe, Laila Shah, Catherine M Sackley, Katherine HO Deane, Clare P Herd, Keith Wheatley, Natalie Ives, Physiotherapy versus placebo or no intervention in Parkinson's disease, The Cochrane Library,
    Direct Link:
  50. 50
    Claire L Tomlinson, Smitaa Patel, Charmaine Meek, Carl E Clarke, Rebecca Stowe, Laila Shah, Catherine M Sackley, Katherine HO Deane, Clare P Herd, Keith Wheatley, Natalie Ives, Physiotherapy versus placebo or no intervention in Parkinson's disease, The Cochrane Library,
    Direct Link:
  51. 51
    Claire L Tomlinson, Smitaa Patel, Charmaine Meek, Carl E Clarke, Rebecca Stowe, Laila Shah, Catherine Sackley, Katherine HO Deane, Keith Wheatley, Natalie Ives, Physiotherapy versus placebo or no intervention in Parkinson's disease, The Cochrane Library,
    Direct Link:
View Full Article (HTML) Get PDF (76K)